Effect of Heart Valve Replacement on Cheyne-Stokes Respiration (CSR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01426776|
Recruitment Status : Completed
First Posted : August 31, 2011
Last Update Posted : July 25, 2012
|Condition or disease||Intervention/treatment||Phase|
|Cheyne-Stokes Respiration Heart Valve Disease Central Sleep Apnea||Procedure: heart valve replacement||Not Applicable|
Sleep apnea, especially central sleep apnea, has a high prevalence in patients with chronic heart failure. Although sleep disordered breathing (SDB) have been described in patients with heart disease, the prevalence is not known because: ①There are various forms of SDBs, including obstructive sleep apnea(OSA), central sleep apnea (CSA), and mixed forms of sleep apnea syndromes that have variable prevalence; ②Patients suffering from rheumatic valve disease usually have varying degrees of heart failure, and this variability affects estimates of prevalence; ③There are no international patient registries and SDB is underdiagnosed in many parts of the world.
The previous studies are most focusing on nonvalvular disease. We ①investigate the prevalence and the risk factors of Cheyne-Stokes respiration in patients with heart valve diseases, ②compare the changes of parameters of Cheyne-Stokes Respiration and heart function (like apnea hypopnea index, pulse oxygen saturation, blood pressure, echocardiogram, electrocardiogram, 6-minute walk test) before heart valve replacement and 3, 6, and 12 months after the surgery.
With nocturnal polysomnography (PSG) examination 30 patients typical CSR are going to be screened out from 300 patients with heart valve disease and waiting for cardiac surgery. The Comparison of 30 patients undergoing heart valve replacement will be performed before and 3, 6, and 12 months following heart valve replacement. We shall analyze the changes of CSR before and after valve replacement as well as the correlation among cardiac function and PSG parameters.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||26 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Effect of Heart Valve Replacement on Cheyne-Stokes Respiration in Patients With Rheumatic Heart Disease|
|Study Start Date :||September 2010|
|Actual Primary Completion Date :||February 2012|
|Actual Study Completion Date :||July 2012|
|heart valve replacement||
Procedure: heart valve replacement
The patients with heart valve disease and CSR will be received heart valve replacement
Other Name: cardiac surgery
- Changes of CSR index before and 3, 6, 12 months following valve replacement. [ Time Frame: 1 year after cardiac surgery of each enrolled patient ]The primary goal of this study is to compare the changes of polysomnography(PSG) parameters(index of CSR, apnea hypopnea index, pulse oxygen saturation, etc)before and 3, 6, 12 months following the cardiac valve replacement surgery.
- Association of PSG parameters with cardiac function before and 3, 6, 12 months following valve replacement [ Time Frame: 1 year after cardiac surgery of each enrolled patient ]The secondary goal of this study is to determine the association of PSG parameters(index of CSR, apnea hypopnea index, pulse oxygen saturation, electrocardiogram, etc)and cardiac function (LVEF, 6-minute walk test, etc) before and 3, 6, 12 months following the cardiac valve replacement surgery. Qualities of life and sleep will also be masured before and 3, 6, 12 months after surgery. (The quality of life is assessed by reference to "The Medical Outcomes Study 36item Short-Form Health Survey"(SF-36) generic questionnaire, and sleep quality is assessed by Pittsburgh Sleep Quality Index(PSQI).)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01426776
|The First Affiliated Hospital of Nanjing Medical University|
|Nanjing, Jiangsu, China, 210029|
|Study Director:||Shijiang Zhang, MD||The First Affiliated Hospital with Nanjing Medical University|
|Principal Investigator:||Ning Ding, Doctor||The First Affiliated Hospital with Nanjing Medical University|